|
ImmuPharma PLC - specialist drug discovery and development company - Widens its pretax loss to £8.9 million in 2021 from £7.2 million loss the previous year. Loss includes exceptional costs in respect of corporate reorganisation and respective settlement arrangements, company adds. Revenue drops 6.6% to £118,350 from £126,667. Research and development expenses surge to £3.7 million from £2.4 million. P140-related expenditure was the main reason for this increase. P140, also known as Llupuzor, is a potential treatment for Lupus. Company does not propose a dividend.
Chief Executive Tim McCarthy says: ‘With now a fully reviewed and assessed R&D development pipeline, we remain focused on bringing our two late-stage clinical assets, Lupuzor and P140 for CIDP closer to the market. Specifically, on Lupuzor, our partner Avion, is committed to moving this program into Phase 3 as soon as possible, following final discussions with the FDA and based on the positive readout of the recent PK study.’
Current stock price: 5.30 pence, down 9.9% in London
12-month change: down 43%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
